Free Trial

Bio-Rad Laboratories (BIO.B) Competitors

Bio-Rad Laboratories logo
$250.08 0.00 (0.00%)
As of 06/27/2025

BIO.B vs. VLTO, FTV, TER, RVTY, AVTR, NVMI, VNT, MIR, ST, and CAMT

Should you be buying Bio-Rad Laboratories stock or one of its competitors? The main competitors of Bio-Rad Laboratories include Veralto (VLTO), Fortive (FTV), Teradyne (TER), Revvity (RVTY), Avantor (AVTR), Nova (NVMI), Vontier (VNT), Mirion Technologies (MIR), Sensata Technologies (ST), and Camtek (CAMT). These companies are all part of the "measuring and control equipment" industry.

Bio-Rad Laboratories vs. Its Competitors

Bio-Rad Laboratories (NYSE:BIO.B) and Veralto (NYSE:VLTO) are both measuring and control equipment companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Veralto has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Veralto, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.57B2.65-$1.84B-$76.20-3.28
Veralto$5.19B4.82$833M$3.5028.87

In the previous week, Veralto had 14 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 14 mentions for Veralto and 0 mentions for Bio-Rad Laboratories. Veralto's average media sentiment score of 1.38 beat Bio-Rad Laboratories' score of 0.00 indicating that Veralto is being referred to more favorably in the news media.

Company Overall Sentiment
Bio-Rad Laboratories Neutral
Veralto Positive

0.0% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 91.3% of Veralto shares are held by institutional investors. 28.4% of Bio-Rad Laboratories shares are held by insiders. Comparatively, 0.4% of Veralto shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Veralto has a net margin of 16.56% compared to Bio-Rad Laboratories' net margin of -85.16%. Veralto's return on equity of 45.63% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories-85.16% 4.32% 3.03%
Veralto 16.56%45.63%14.45%

Veralto has a consensus price target of $110.09, indicating a potential upside of 8.97%. Given Veralto's stronger consensus rating and higher possible upside, analysts clearly believe Veralto is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Veralto
0 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.45

Bio-Rad Laboratories has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Veralto has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.

Summary

Veralto beats Bio-Rad Laboratories on 15 of the 16 factors compared between the two stocks.

Get Bio-Rad Laboratories News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIO.B and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIO.B and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIO.B vs. The Competition

MetricBio-Rad LaboratoriesMED IndustryMedical SectorNYSE Exchange
Market Cap$6.81B$2.84B$5.46B$20.29B
Dividend YieldN/A2.70%5.36%3.76%
P/E Ratio-3.2821.1526.4427.49
Price / Sales2.65259.51405.3238.28
Price / Cash24.0641.2925.8817.85
Price / Book1.077.247.944.54
Net Income-$1.84B-$55.05M$3.15B$985.09M
7 Day PerformanceN/A-1.01%0.63%0.88%
1 Month PerformanceN/A5.98%4.96%4.04%
1 Year Performance-11.77%0.83%32.55%13.29%

Bio-Rad Laboratories Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIO.B
Bio-Rad Laboratories
N/A$250.08
flat
N/A-11.8%$6.81B$2.57B-3.288,200
VLTO
Veralto
3.0359 of 5 stars
$98.45
+1.8%
$110.09
+11.8%
+5.8%$23.98B$5.19B28.1317,000Positive News
FTV
Fortive
4.9269 of 5 stars
$70.32
+1.0%
$82.62
+17.5%
-29.6%$23.67B$6.23B30.8418,000News Coverage
Gap Down
TER
Teradyne
4.9513 of 5 stars
$87.36
+1.2%
$114.67
+31.3%
-39.4%$13.84B$2.82B24.686,500Positive News
RVTY
Revvity
3.8047 of 5 stars
$95.01
+0.0%
$125.64
+32.2%
-7.6%$11.20B$2.76B40.4311,000Analyst Upgrade
AVTR
Avantor
4.9808 of 5 stars
$13.45
-0.9%
$18.88
+40.3%
-36.4%$9.25B$6.78B12.9313,500News Coverage
Positive News
NVMI
Nova
1.8434 of 5 stars
$234.10
+1.3%
$277.00
+18.3%
+17.3%$6.80B$672.40M35.364,149Positive News
Gap Up
VNT
Vontier
3.4327 of 5 stars
$36.28
+1.5%
$44.83
+23.6%
-3.3%$5.29B$2.98B14.758,000
MIR
Mirion Technologies
0.8176 of 5 stars
$20.33
+3.5%
$18.75
-7.8%
+101.0%$4.56B$860.80M-338.832,860High Trading Volume
ST
Sensata Technologies
4.6148 of 5 stars
$28.63
+1.3%
$34.08
+19.0%
-19.4%$4.14B$3.93B35.3519,000
CAMT
Camtek
2.9615 of 5 stars
$74.85
+1.2%
$90.78
+21.3%
-32.5%$3.37B$429.23M28.68400

Related Companies and Tools


This page (NYSE:BIO.B) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners